01957nas a2200361   4500000000100000008004100001260001300042653001500055653001000070653001000080653001100090653004300101653001200144653003000156653001100186653001100197653001200208653000900220653001600229653001300245653001600258653001500274100001500289700001300304700002200317700001600339245010400355856004100459300001000500490000700510520106400517022001401581       1983                            d  c1983 Dec10aAdolescent10aAdult10aAging10aAmides10aChemical and Drug Induced Liver Injury10aDapsone10aDrug Therapy, Combination10aFemale10aHumans10aleprosy10aMale10aMiddle Aged10aRifampin10aSex Factors10aThioamides1 aCartel J L1 aMillan J1 aGuelpa-Lauras C C1 aGrosset J H00aHepatitis in leprosy patients treated by a daily combination of dapsone, rifampin, and a thioamide.  uhttp://ila.ilsl.br/pdfs/v51n4a01.pdf  a461-50 v513 a<p>A 13% incidence of hepatitis was observed among 54 cases of multibacillary leprosy treated daily with the three-drug combination of dapsone, rifampin, and a thioamide (ethionamide or prothionamide). No hepatitis was observed among 109 cases of paucibacillary leprosy treated daily with the two-drug combination of dapsone and rifampin. Symptoms were jaundice in five cases and nausea plus vomiting associated with a significant increase of transaminase levels in two cases. In five cases, the symptoms appeared during the first two months of therapy and in two cases, later. Discontinuing treatment with rifampin and the thioamide but not dapsone resulted in recovery. When rifampin was resumed without the thioamide, the hepatitis did not recur. Viral etiology could be eliminated in six cases. Neither sex, age, weight nor the fact that the patient was a new case or a relapse case appeared to be a contributing factor. Hepatotoxicity caused by administration of a thioamide might have been potentiated by the concurrent administration of rifampin.</p>
  a0148-916X